1 August 2020 - The August 2020 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The August issue of the Schedule includes a number of new/revised listings:

• Botulinum toxin type A (Xeomin) - restriction change
• Entretinib (Rozlytrek) - new medicine
• Lorlatinib (Lorviqua) - new medicine
• Olaparib (Lynparza) - new indication
• Pegfilgrastim (Pelgraz) - new biosimilar medicine
• Stiripentol (Diacomit) - new medicine
• Tocilizumab (Actemra) - new formulation

Read Summary of PBS Changes